Advanced Filters
noise

Roeselare, Australia Clinical Trials

A listing of Roeselare, Australia clinical trials actively recruiting patients volunteers.

Found 64,712 clinical trials
N Nina D Anfinogenova, PhD

Registry of Acute Myocardial Infarction

The Registry of Acute Myocardial Infarction (RAMI) aims at regular and centralized acquiring and processing standard information about verified and suspected cases of acute myocardial infarction (AMI), monitoring of AMI cases, and establishing AMI diagnosis based on standard diagnostic criteria by doctors involved in the registry. The RAMI obtains data …

20 years of age All Phase N/A
I Ilda Bander

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) administered to participants with progressive PSMA-positive metastatic castration-resistant prostate cancer. The study will also characterize the risk of QT prolongation …

18 - 100 years of age Male Phase 2
T Tao Sun

Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD

A placebo-controlled superiority design was used to evaluate the efficacy of 60 mg/ day or 120 mg/ day of Buagafuran capsules in the treatment of GAD

18 - 65 years of age All Phase 3
S Sonobia Garrett, BSHS

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

This is a multi-center study and the aim is to develop and validate an Artificial Intelligence (AI) -based histologic analysis tool to predict responsiveness to intravesical Bacillus Calmette-Guérin (BCG) and intravesical chemotherapy in intermediate and high-risk non-muscle invasive bladder cancer patients.

18 - 99 years of age All Phase N/A

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children \< 2 years of age genetically diagnosed with …

3 - 24 years of age All Phase 4
E Emmanuel Poulet, MD

Evaluation of the Safety Plan to Prevent Suicidal Reiteration

Each year, suicide is the cause of 8,580 deaths in France, it is the second leading cause of death among 15-24 year olds. People who have made a first suicide attempt are identified as being at greater risk of repeating a suicidal gesture, particularly in the first month following the …

18 - 65 years of age All Phase N/A

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.

1 - 18 years of age All Phase 3

Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

The goal of this clinical biomarker validation trial is to test the effect of a predictive biomarker panel to human albumin infusions in patients with liver cirrhosis and ascites. The main questions it aims to answer are: If the predictive biomarker panel can identify patients who are likely to benefit …

18 years of age All Phase 3
L LIFE Child

LIFE Child (LIFE Leipzig Research Centre for Civilization Diseases)

The Leipzig Research Centre for Civilization Diseases (LIFE) Child Study is a prospective longitudinal population-based study with a life course approach to health and disease. The LIFE Child Study focuses on two main research objectives: What are premises of normal growth, development and health in children? Which factors contribute to …

- 20 years of age All Phase N/A
M Michelle vanDellen, PhD

Dyadic Financial Incentive Treatments for Dual Smoker Couples

Smokers partnered with other smokers (i.e., dual-smoker couples) represent \~2/3 of all smokers. Dual-smoker couples (DSCs) are less likely to try to quit smoking and more likely to relapse during a quit attempt, reducing overall smoking cessation rates and representing a high-risk clinical population. Despite their high prevalence and risk …

18 years of age All Phase 2

Simplify language using AI